Paul Tudor Jones’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-143,115
Closed -$7.4M 4020
2026
Q1
$7.27M Buy
143,115
+46,909
+49% +$2.19M 0.01% 938
2025
Q4
$2.84M Sell
96,206
-248,345
-72% -$6.75M 0.01% 1556
2025
Q3
$8.9M Sell
344,551
-191,114
-36% -$5.33M 0.02% 828
2025
Q2
$14.8M Buy
535,665
+219,273
+69% +$5.77M 0.03% 479
2025
Q1
$8.97M Sell
316,392
-37,473
-11% -$1.33M 0.03% 512
2024
Q4
$14.7M Buy
353,865
+200,767
+131% +$9.6M 0.06% 220
2024
Q3
$10.2M Buy
153,098
+28,763
+23% +$2.64M 0.04% 408
2024
Q2
$14.8M Buy
+124,335
New +$15.7M 0.08% 247
2023
Q1
Sell
-9,779
Closed -$1.76M 2761
2022
Q4
$1.76M Sell
9,779
-26,582
-73% -$4.35M 0.03% 714
2022
Q3
$4.3M Buy
36,361
+22,026
+154% +$3.34M 0.09% 259
2022
Q2
$2.05M Buy
14,335
+8,502
+146% +$1.22M 0.05% 501
2022
Q1
$1M Sell
5,833
-3,849
-40% -$648K 0.02% 914
2021
Q4
$2.46M Sell
9,682
-14,215
-59% -$4.16M 0.04% 539
2021
Q3
$9.2M Buy
23,897
+14,618
+158% +$5.39M 0.15% 112
2021
Q2
$2.18M Sell
9,279
-19,487
-68% -$3.48M 0.04% 521
2021
Q1
$3.77M Buy
28,766
+18,821
+189% +$2.73M 0.08% 267
2020
Q4
$1.04M Buy
9,945
+1,707
+21% +$173K 0.03% 686
2020
Q3
$583K Buy
+8,238
New +$574K 0.03% 757

Other funds holding MRNA

Paul Tudor Jones's MRNA Position: Q2 2026 in Review

Paul Tudor Jones sold out of Moderna (MRNA) in Q2 2026, closing a stake of 143,115 shares — an estimated $7.4M sold.

Paul Tudor Jones first reported a position in MRNA in Q3 2020 and held it in 18 quarters. The position peaked at $14.8M in Q2 2025. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Paul Tudor Jones reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 143,115 Moderna shares in Q2 2026, an estimated $7.4M.
  • Paul Tudor Jones first reported a position in Moderna in Q3 2020 and held it in 18 quarters.
  • Paul Tudor Jones's Moderna position peaked at $14.8M in Q2 2025.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.